01 February 2004
G-CSF in solid tumor chemotherapy: a tailored regimen reduces febrile neutropenia, treatment delays and direct costs
Nicolas Tsavaris, Christos Kosmas, Panagiotis Gouveris, Maria Vadiak, Antonis Dimitrakopoulos, Dimitra Karadima, Efterpi Pagouni, George Panagiotakopoulos, Evanthia Tzima, Sevasti Ispoglou, Dimitris Sakelariou, Christos KoufosMed Sci Monit 2004; 10(2): PI24-28 :: ID: 11583
Abstract
Background:Current guidelines do not recommend G-CSF for patients with risk factors for neutropenia.Material/Methods: One-hundred patients undergoing chemotherapy were randomized to treatment with G-CSF at 5 Kg/kg for established febrile neutropenia (ANC <1000/micro l) (Group A) or G-CSF at 263 Kg/day if ANC was 1500/micro l or less on the day of the expected nadir, with the duration of treatment determined by the severity of neutropenia (Group B).
Results: The number of doses of G-CSF was similar in the two groups. There were 34 cases of febrile neutropenia in Group A, but none in Group B (p=0.0001). Hospital admission for febrile neutropenia, antibiotic use and delays in chemotherapy were all significantly more common in Group A. Total direct costs were estimated to be € 66, 646 for Group A and € 47, 119 for Group B.
Conclusions: Tailoring treatment does not increase G-CSF use, but significantly reduces febrile neutropenia and treatment delays and lowers direct costs.
Keywords: Antineoplastic Combined Chemotherapy Protocols - administration & dosage, Antineoplastic Combined Chemotherapy Protocols - economics, Drug Administration Schedule, Fever - blood, Fever - complications, Fever - drug therapy, Granulocyte Colony-Stimulating Factor - administration & dosage, Granulocyte Colony-Stimulating Factor - economics, Leukocyte Count, Neoplasms - blood, Neoplasms - complications, Neoplasms - drug therapy, Neutropenia - blood, Neutropenia - complications, Neutropenia - drug therapy, Neutrophils - cytology, Neutrophils - drug effects, Antineoplastic Combined Chemotherapy Protocols - economics, Drug Administration Schedule, Fever - drug therapy, Granulocyte Colony-Stimulating Factor - economics, Leukocyte Count, Neoplasms - drug therapy, Neutropenia - drug therapy, Neutrophils - drug effects
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Comparing Neuromuscular Blockade Measurement Between Upper Arm (TOF Cuff®) and Eyelid (TOF Scan®) Using Miv...Med Sci Monit In Press; DOI: 10.12659/MSM.943630
11 Mar 2024 : Clinical Research
Enhancement of Frozen-Thawed Human Sperm Quality with Zinc as a Cryoprotective AdditiveMed Sci Monit In Press; DOI: 10.12659/MSM.942946
12 Mar 2024 : Database Analysis
Risk Factors of Age-Related Macular Degeneration in a Population-Based Study: Results from SHIP-TREND-1 (St...Med Sci Monit In Press; DOI: 10.12659/MSM.943140
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952